EP33 – TWIST1 and ANLN gene expressions may be relevant to identify thyroid neoplasias with malignant prognosis

     

    Mato, Eugenia1; González, Cintia2,1; Blanco, Rosa Mª1; Moral, Antonio3; Pérez, José Ignacio3; de Leiva, Alberto2,1
    1 Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)
    2 Department of Endocrinology-EDUAB-HSP , Hospital de Sant Pau, Autonomous University, Barcelona, Spain
    3 General Surgery, Hospital de Sant Pau, Autonomous University, Barcelona, Spain

     

    Background/ Purpose: Epithelial-Mesenchymal transition process (EMT) induces tumoral progression in epithelial thyroid neoplasia (ETN). However, it is unknown which genes involved in EMT contribute to the malignization of these tumors. The aim was to analyze the expression profile of: E-Cadherin (CDH1), Survivin (BIRC5), Interleukin 1 receptor antagonist (IL1RN), basic helix-loop-helix, transcription factor 1 (TWIST1), Anillin (ANL) genes and investigate their relationship with the  prognosis in a cohort of patients affected with ETN. RNA from thyroid tissue samples (n=122) classified into Adenomas (n=38), Papillary Carcinoma (PTC) n=56; Follicular Carcinoma (FTC) n=14; Poorly Differentiated Carcinoma (PDCT) n=14. Tissue RNA was reversely transcribed and the cDNA was analyzed by TaqMan_ Array Card in an ABI PRISM 7900HF, using cDNA from normal thyroid tissue as control.

    Method: The relative expressions were calculated using the 2-DDCt method, SDS2.3 and Data Assist V2.1 softwares.

    Results: In PTC, the BIRC5 and ANLN genes were significantly down-regulated while CDH1, IL1RN and TWIST1 were over-expressed.  In FTC, CDH1 and IL1RN genes were significantly over-expressed; TWIST1 showed a trend for over-expression. BIRC5 showed down-regulation and ANLN did not present any change. In PDCT all genes showed up-expression. In adenomas, most significantly, TWIST1 gene did not show any change.

    Conclusion: TWIST1 gene expression could help to differentiate benign versus malignant ETN, and ANLN gene expression to identify thyroid neoplasias with aggressive behavior.

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    Rome, Italy | 2019

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts